You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.

Alliance:

  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

Pre-Close Trading Update - 13 Jul 2015

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces its pre-close trading update ahead of the announcement of its interim results for the six months ended 30 June 2015.

The Group continues to perform well and in line with management's expectations, with sales of approximately £22.8m (H1 2014: £21.4m) in the first half of the year.

Our growth products continue to deliver, with Hydromol™ generating sales of £3.3m in the period, 10% higher than in the same period in the prior year despite the additional PPRS rebate deduction.

MacuShield™, acquired in February this year, is performing in line with expectations and we look forward to the return of ImmuCyst in the second half of the year, although volumes remain uncertain as Sanofi's facility ramps up production.

Alliance continues to explore a number of acquisition opportunities and remains confident of the outlook for the full year.

The Company's interim results for the six months ended 30 June 2015 are scheduled to be released on 9 September 2015.

For further information:

Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer

Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black

Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.